亿胜生物科技：与复宏汉霖就渗出性(湿性)老年性黄斑部病变的治疗共同开发许可产品国际多中心三期临床研究完成最后一名患者的最后一次访视

格隆汇2025-01-06

格隆汇1月6日丨亿胜生物科技(01061.HK)公布，有关受许人(均为公司全资附属公司)与复宏汉霖订立共同开发许可协议，以根据共同开发许可协议之条款共同开发许可产品及向受许人授出有关许可产品之独家权利。用以治疗湿性AMD之anti-VEGF眼用注射生物药品HLX04-O的国际多中心三期临床研究近日完成最后一名患者的最后一次访视。此三期临床研究是一项在湿性AMD患者中开展的随机、双盲、阳性对照及全球...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2501407953?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-06 16:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2501407953","market":"hk","top_or_hot":-1,"title":"亿胜生物科技：与复宏汉霖就渗出性(湿性)老年性黄斑部病变的治疗共同开发许可产品国际多中心三期临床研究完成最后一名患者的最后一次访视","media":"格隆汇","content":"<div>\n<p>格隆汇1月6日丨亿胜生物科技(01061.HK)公布，有关受许人(均为公司全资附属公司)与复宏汉霖订立共同开发许可协议，以根据共同开发许可协议之条款共同开发许可产品及向受许人授出有关许可产品之独家权利。用以治疗湿性AMD之anti-VEGF眼用注射生物药品HLX04-O的国际多中心三期临床研究近日完成最后一名患者的最后一次访视。此三期临床研究是一项在湿性AMD患者中开展的随机、双盲、阳性对照及全球...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106163350aba03105&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>亿胜生物科技：与复宏汉霖就渗出性(湿性)老年性黄斑部病变的治疗共同开发许可产品国际多中心三期临床研究完成最后一名患者的最后一次访视</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n亿胜生物科技：与复宏汉霖就渗出性(湿性)老年性黄斑部病变的治疗共同开发许可产品国际多中心三期临床研究完成最后一名患者的最后一次访视\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-06 16:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106163350aba03105&s=b><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇1月6日丨亿胜生物科技(01061.HK)公布，有关受许人(均为公司全资附属公司)与复宏汉霖订立共同开发许可协议，以根据共同开发许可协议之条款共同开发许可产品及向受许人授出有关许可产品之独家权利。用以治疗湿性AMD之anti-VEGF眼用注射生物药品HLX04-O的国际多中心三期临床研究近日完成最后一名患者的最后一次访视。此三期临床研究是一项在湿性AMD患者中开展的随机、双盲、阳性对照及全球...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106163350aba03105&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106163350aba03105&s=b","article_id":"2501407953","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106163350aba03105&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2501407953","pubTimestamp":1736152430,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇1月6日丨亿胜生物科技公布，有关受许人与复宏汉霖订立共同开发许可协议，以根据共同开发许可协议之条款共同开发许可产品及向受许人授出有关许可产品之独家权利。用以治疗湿性AMD之anti-VEGF眼用注射生物药品HLX04-O的国际多中心三期临床研究近日完成最后一名患者的最后一次访视。此三期临床研究是一项在湿性AMD患者中开展的随机、双盲、阳性对照及全球的研究，旨在比较HLX04-O与雷珠单抗的有效性和安全性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","01061":"亿胜生物科技","02696":"复宏汉霖"},"translate_title":"Essex Biotechnology: Completed the last visit of the last patient in the international multi-center phase III clinical study of co-development of licensed products with Henlius for the treatment of exudative (wet) age-related macular degeneration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1,"02696":1},"content_text":"格隆汇1月6日丨亿胜生物科技(01061.HK)公布，有关受许人(均为公司全资附属公司)与复宏汉霖订立共同开发许可协议，以根据共同开发许可协议之条款共同开发许可产品及向受许人授出有关许可产品之独家权利。用以治疗湿性AMD之anti-VEGF眼用注射生物药品HLX04-O的国际多中心三期临床研究近日完成最后一名患者的最后一次访视。此三期临床研究是一项在湿性AMD患者中开展的随机、双盲、阳性对照及全球的研究，旨在比较HLX04-O与雷珠单抗的有效性和安全性。合格的受试者将以1:1的比例随机分为两组，分别于48周内每四周玻璃体腔内注射HLX04-O( 1.25毫克)或雷珠单抗( 0.5毫克)。本次研究的主要目的为比较第36周HLX04-O与雷珠单抗在湿性AMD患者研究眼中的有效性，主要终点为第36周最佳矫正视力(BCVA)较基线改善的平均字母数变化，次要目的包括评估其它疗效终点、安全性、耐受性及药代动力学特征。HLX04-O是在复宏汉霖自主研发的汉贝泰®(贝伐珠单抗注射液)的基础上，根据眼科用药的需求对汉贝泰®(贝伐珠单抗注射液)的处方、规格和生产工艺进行优化，在活性成分不变的基础上，开发的新的眼科制剂产品，拟用于湿性AMD的治疗。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501407953","isCrawlerRequest":true}